AR029657A1 - Compuesto derivado de sulfonil piperidina o piperazina, composicion farmaceutica que lo comprende, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por enzimas metaloproteinasas y procesos para su preparacion - Google Patents
Compuesto derivado de sulfonil piperidina o piperazina, composicion farmaceutica que lo comprende, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por enzimas metaloproteinasas y procesos para su preparacionInfo
- Publication number
- AR029657A1 AR029657A1 ARP010100790A ARP010100790A AR029657A1 AR 029657 A1 AR029657 A1 AR 029657A1 AR P010100790 A ARP010100790 A AR P010100790A AR P010100790 A ARP010100790 A AR P010100790A AR 029657 A1 AR029657 A1 AR 029657A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- alkyl
- preparation
- pyridyl
- monosubstituted
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- XPYOORHZRLSTSG-UHFFFAOYSA-N 2-sulfonylpiperidine Chemical compound O=S(=O)=C1CCCCN1 XPYOORHZRLSTSG-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 abstract 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- -1 2-pyridyloxy Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940091173 hydantoin Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto derivado de sulfonil piperidina y piperazina de la formula (1) o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo, donde B representa un grupo fenilo monosustituido en la posicion 3 o 4 por halogeno o trifluorometilo, o disustituido en las posiciones 3 y 4 por halogeno (que puede ser el mismo o diferente);o B representa un grupo 2-piridilo o 2-piridiloxi monosustituido en la posicion 4, 5, o 6 con halogeno, trifuorometilo, ciano o alquilo C1-4, o B representa un grupo 4-pirimidinilo optativamente sustituido en la posicion 6 por halogeno o C1-4 alquilo; X representa un átomo de carbono o de nitrogeno; R1 representa un grupo trimetil-1-hidantoin C2-4 alquilo o un grupo trimetil-3-hidantoion C2-4 alquilo; fenilo o C2-4alquilfenilo monosustituido en la posicion 3 o 4 por halogeno, trifluorometilo, tio o C1-3 alquilo o C1-3 alcoxi; fenill-SO2NHC2-4alquilo; 2-piridilo o 2-piridil C2-4alquilo; 3-piridilo o 3-piridil C2-4 alquilo; 2-pirimidina-SCH2CH2; 2- o 4-pirimidinil C2-4 alquilo optativamente monosustituidos por uno entre halogeno, trifluorometilo C1-3 alquilo, C1-3 alquiloxi, 2-pirazinilo optativamente sustituido por halogeno o 2-pirazinilo C2-4 alquilo optativamente sustituido por halogeno. También se describen composiciones farmacéuticas que los comprenden así como el uso de dichos compuestos en la preparacion de medicamentos utiles como inhibidores de metaloproteinasas, especialmente como inhibidores de la MMP 13. Procesos para la preparacion de dichos compuestos también se detallan
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00400467 | 2000-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029657A1 true AR029657A1 (es) | 2003-07-10 |
Family
ID=8173564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100790A AR029657A1 (es) | 2000-02-21 | 2001-02-21 | Compuesto derivado de sulfonil piperidina o piperazina, composicion farmaceutica que lo comprende, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por enzimas metaloproteinasas y procesos para su preparacion |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US6734183B2 (es) |
| EP (1) | EP1261590B1 (es) |
| JP (1) | JP4256095B2 (es) |
| KR (1) | KR20020073594A (es) |
| CN (1) | CN1247547C (es) |
| AR (1) | AR029657A1 (es) |
| AT (1) | ATE553097T1 (es) |
| AU (1) | AU783284B2 (es) |
| BG (1) | BG65276B1 (es) |
| BR (1) | BR0108501A (es) |
| CA (1) | CA2396965C (es) |
| CO (1) | CO5241356A1 (es) |
| CZ (1) | CZ20022828A3 (es) |
| EE (1) | EE200200462A (es) |
| HU (1) | HUP0302723A3 (es) |
| IL (1) | IL150806A0 (es) |
| IS (1) | IS6507A (es) |
| MX (1) | MXPA02008111A (es) |
| MY (1) | MY128164A (es) |
| NO (1) | NO323765B1 (es) |
| NZ (1) | NZ520104A (es) |
| PL (1) | PL365909A1 (es) |
| RU (1) | RU2283306C2 (es) |
| SA (1) | SA01220167B1 (es) |
| SG (1) | SG127737A1 (es) |
| SK (1) | SK287071B6 (es) |
| TW (1) | TWI276632B (es) |
| UA (1) | UA73155C2 (es) |
| WO (1) | WO2001062742A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
| GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| ES2319970T3 (es) | 2001-09-07 | 2009-05-18 | Kaken Pharmaceutical Co., Ltd. | Derivados de acido hidroxamico inverso. |
| SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
| EP1657240A4 (en) | 2003-08-18 | 2009-04-08 | Fujifilm Finechemicals Co Ltd | PYRIDYLTETRAHYDROPYRIDINE, PYRIDYLPIPERIDINE AND METHOD FOR THE PRODUCTION THEREOF |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| AU2006316552B2 (en) * | 2005-11-24 | 2012-06-07 | Merck Serono Sa | N-hydroxyamide derivatives and use thereof |
| GB0617367D0 (en) * | 2006-09-02 | 2006-10-11 | Astrazeneca Ab | Novel process |
| AU2009241365B2 (en) | 2008-04-28 | 2015-01-22 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| HUE030114T2 (en) * | 2010-07-08 | 2017-04-28 | Kaken Pharma Co Ltd | N-hydroxyformamide derivatives and pharmaceutical compositions containing them |
| PL3116859T3 (pl) * | 2014-03-12 | 2019-04-30 | Chong Kun Dang Pharmaceutical Corp | Nowe związki jako inhibitory deacetylazy histonowej 6 i zawierające je kompozycje farmaceutyczne |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA19045A (uk) * | 1988-02-24 | 1997-12-25 | Ф.Хофманн - Ля Рош Аг | Спосіб одержаhhя похідhих стильбеhу |
| HU218480B (hu) * | 1995-06-15 | 2000-09-28 | BIOREX Kutató és Fejlesztő Rt. | Hidroxilaminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények |
| WO1998016514A1 (en) | 1996-10-16 | 1998-04-23 | American Cyanamid Company | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| WO1998032748A1 (en) * | 1997-01-23 | 1998-07-30 | F. Hoffmann-La Roche Ag | Sulfamide-metalloprotease inhibitors |
| US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
| ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
| US6482827B1 (en) | 1997-07-10 | 2002-11-19 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
| EP0925289A1 (en) * | 1997-07-10 | 1999-06-30 | PHARMACIA & UPJOHN S.p.A. | Matrix metalloproteinase inhibitors |
| US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6130220A (en) | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
| US6100266A (en) * | 1998-01-30 | 2000-08-08 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
| WO2000012477A1 (en) | 1998-08-29 | 2000-03-09 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as proteinase inhibitors |
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
-
2001
- 2001-02-15 WO PCT/GB2001/000624 patent/WO2001062742A1/en not_active Ceased
- 2001-02-15 RU RU2002118301/04A patent/RU2283306C2/ru not_active IP Right Cessation
- 2001-02-15 CA CA2396965A patent/CA2396965C/en not_active Expired - Fee Related
- 2001-02-15 UA UA2002075698A patent/UA73155C2/uk unknown
- 2001-02-15 JP JP2001562524A patent/JP4256095B2/ja not_active Expired - Fee Related
- 2001-02-15 HU HU0302723A patent/HUP0302723A3/hu unknown
- 2001-02-15 EE EEP200200462A patent/EE200200462A/xx unknown
- 2001-02-15 PL PL01365909A patent/PL365909A1/xx not_active Application Discontinuation
- 2001-02-15 SG SG200404773A patent/SG127737A1/en unknown
- 2001-02-15 NZ NZ520104A patent/NZ520104A/en unknown
- 2001-02-15 EP EP01905885A patent/EP1261590B1/en not_active Expired - Lifetime
- 2001-02-15 AT AT01905885T patent/ATE553097T1/de active
- 2001-02-15 CZ CZ20022828A patent/CZ20022828A3/cs unknown
- 2001-02-15 IL IL15080601A patent/IL150806A0/xx not_active IP Right Cessation
- 2001-02-15 MX MXPA02008111A patent/MXPA02008111A/es active IP Right Grant
- 2001-02-15 SK SK1197-2002A patent/SK287071B6/sk not_active IP Right Cessation
- 2001-02-15 BR BR0108501-8A patent/BR0108501A/pt not_active Application Discontinuation
- 2001-02-15 KR KR1020027010762A patent/KR20020073594A/ko not_active Ceased
- 2001-02-15 CN CNB018053920A patent/CN1247547C/zh not_active Expired - Fee Related
- 2001-02-15 AU AU33855/01A patent/AU783284B2/en not_active Ceased
- 2001-02-19 MY MYPI20010723A patent/MY128164A/en unknown
- 2001-02-20 CO CO01013250A patent/CO5241356A1/es not_active Application Discontinuation
- 2001-02-21 US US09/788,687 patent/US6734183B2/en not_active Expired - Fee Related
- 2001-02-21 AR ARP010100790A patent/AR029657A1/es not_active Application Discontinuation
- 2001-02-27 TW TW090104516A patent/TWI276632B/zh not_active IP Right Cessation
- 2001-06-23 SA SA01220167A patent/SA01220167B1/ar unknown
-
2002
- 2002-08-14 BG BG107003A patent/BG65276B1/bg unknown
- 2002-08-16 IS IS6507A patent/IS6507A/is unknown
- 2002-08-20 NO NO20023956A patent/NO323765B1/no not_active IP Right Cessation
-
2004
- 2004-02-26 US US10/787,813 patent/US7122551B2/en not_active Expired - Fee Related
-
2006
- 2006-08-24 US US11/509,490 patent/US20060287338A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029657A1 (es) | Compuesto derivado de sulfonil piperidina o piperazina, composicion farmaceutica que lo comprende, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por enzimas metaloproteinasas y procesos para su preparacion | |
| PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
| ECSP045064A (es) | Agonistas receptores de trombina | |
| CY1111822T1 (el) | Παραγωγα σπειροϊνδολινοπιπεριδινης ονες | |
| NO20051165L (no) | Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| DK1864975T3 (da) | Nikotinamid-derivater anvendelige som P38-inhibitorer | |
| NO20060973L (no) | Pyridylderivater og deres anvendelse som tempeutiske midler | |
| EA200100972A1 (ru) | Новые соединения и композиции как ингибиторы протеаз | |
| AR033306A1 (es) | Compuestos | |
| BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
| CY1112960T1 (el) | Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων | |
| CO5611155A2 (es) | Uso de derivado de indolopirrolocarbazol y otro agente anticanceroso en combinacion | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| FI915093A0 (fi) | Sackarinderivat anvaendbara som inhibitorer foer proteolytiskt enzym och deras framstaellning. | |
| EA200800542A1 (ru) | Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4) | |
| BRPI0514386B8 (pt) | bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais | |
| PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
| CY1107473T1 (el) | Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| TR200100895T2 (tr) | Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |